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Introduction: Considering a lack of efficacy data in patients with early rheumatoid arthritis (eRA) presenting
without classical markers of poor prognosis, we compared methotrexate (MTX) with or without step-down
glucocorticoids in the CareRA trial.
Methods: Disease-modifying antirheumatic drug–naïve patients with eRA were stratified into a low-risk group
based on prognostic markers that included non-erosiveness, anti–citrullinated protein antibodies and rheumatoid
factor negativity and low disease activity (Disease Activity Score in 28 joints based on C-reactive protein
(DAS28(CRP)) ≤3.2). Patients were randomized to 15 mg of MTX weekly (MTX with tight step-up (MTX-TSU)) or
15 mg of MTX weekly with prednisone bridging, starting at 30 mg and tapered to 5 mg daily from week 6
(COmbinatie therapie bij Reumatoïde Artritis (COBRA Slim)). A TSU approach was applied. Outcomes assessed were
DAS28(CRP)-determined remission, cumulative disease activity, Health Assessment Questionnaire (HAQ) scores and
adverse events (AEs) after 16 treatment weeks.
Results: We analyzed 43 COBRA Slim and 47 MTX-TSU patients and found that 65.1% in the COBRA Slim group and
46.8% in the MTX-TSU group reached remission (P = 0.081). Mean ± standard deviation area under the curve values
of DAS28(CRP) were 13.84 ± 4.58 and 11.18 ± 4.25 for the MTX-TSU and COBRA Slim patients, respectively (P = 0.006).
More COBRA Slim patients had an HAQ score of 0 (51.2% versus 23.4%, P = 0.006) at week 16. Therapy-related AEs
between groups did not differ.
Conclusion: In patients with low-risk eRA, MTX with step-down glucocorticoid bridging seems more efficacious
than MTX step-up monotherapy, with a comparable number of AEs observed over the first 16 treatment weeks.
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patrick.verschueren@uzleuven.be; diederik.decock@med.kuleuven.be
1Skeletal Biology and Engineering Research Center, KU Leuven Department
of Development and Regeneration, Herestraat 49, 3000 Leuven, Belgium
Full list of author information is available at the end of the article
© 2015 Verschueren et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Verschueren et al. Arthritis Research & Therapy  (2015) 17:97 Page 2 of 7Introduction
Current guidelines recommend treating patients with
early rheumatoid arthritis (eRA) immediately, intensively
and to target [1-3]. Early intensive treatment strategies
combining classical disease-modifying antirheumatic
drugs (DMARDs) with rapid remission-inducing agents
such as glucocorticoids (GCs) or biologicals are the most
effective approach for eRA [4-6]. In daily practice, how-
ever, the initial treatment choice is based on the physi-
cian’s preference, patient and disease characteristics and
cost issues [7]. Traditionally, the absence of bone erosions,
rheumatoid factor (RF) or anti–citrullinated protein anti-
bodies (ACPA) and low disease activity are considered
markers of a good prognosis, but the bad performance of
these markers and derived matrices might lead to under-
treatment of so-called low-risk patients [8].
New, very sensitive classification criteria for rheuma-
toid arthritis (RA) were developed in light of the early
treatment paradigm [9], but patients with eRA still form
a heterogeneous group [10]. Current treatment recom-
mendations are mostly based on evidence from random-
ized controlled trials (RCTs) in preselected populations
with a poor prognosis based on classical markers and
high disease activity. In few studies have researchers ex-
amined how to treat patients in a way not reflective of
this classic RCT image of eRA.
Early intensive treatment appears successful also in pa-
tients with undifferentiated arthritis, including patients
with so-called pre-RA, but confirmation is needed in
studies with a longer follow-up [11]. Some authors, how-
ever, suggest that too stringent treatment targets might
not outweigh the potential side effects in patients with
eRA lacking markers of poor prognosis [12].
In this study, we evaluated the efficacy and safety of
step-up methotrexate (MTX) with or without a step-down
GC bridging scheme after 16 weeks of treatment in pa-
tients with eRA presenting without classical markers of
poor prognosis.
Methods
This study is part of the Care for Early RA (CareRA) trial,
a Flemish, prospective, 2-year, investigator-initiated, multi-
center RCT rooted in daily practice (EudraCT number
2008-007225-39). The trial is conducted in two academic
centers, seven general hospitals and four private practices.
The ethics committee (EC) of the University Hospitals
Leuven approved this study after consultation with the
local ECs. All patients gave us their written informed
consent to participate. The full names of all approving
ECs are provided in the Acknowledgements section.
Patients
DMARD-naïve patients with eRA, as defined by the
American College of Rheumatology 1987 criteria [13],aged ≥18 years and with a disease duration ≤1 year, were
recruited between January 2009 and May 2013. Patients
having contraindications for MTX and/or GCs were ex-
cluded. Additional file 1 describes the exclusion criteria
in more detail.
Eligible patients were stratified into a low- or high-risk
group. This allocation was based on classic RA prognos-
tic factors: presence of erosions, presence of RF or
ACPA, and baseline Disease Activity Score in 28 joints
based on C-reactive protein (DAS28(CRP)).
Patients were considered low risk if they satisfied one
of the following combinations of severity markers:
 No erosions + ACPA- and RF-negative
 Erosions + ACPA- and RF-negative +DAS28(CRP) ≤3.2
 No erosions + ACPA- and/or RF-positive +
DAS28(CRP) ≤3.2
See Figure 1 for more detail about the risk stratification.
Patients were assessed at screening, baseline, week
(W)4, W8 and W16. If a treatment adjustment was re-
quired at W8, an optional visit was held at W12. The
analysis of the first 16 weeks in the high-risk arm of the
CareRA trial was previously reported [14].
Design
Low-risk patients were randomized to one of two treat-
ment arms:
1. MTX tight step-up (MTX-TSU): 15 mg of MTX
weekly, no oral steroids allowed
2. COmbinatie therapie bij Reumatoïde Artritis
(COBRA Slim): 15 mg of MTX weekly with a
step-down scheme of daily oral GCs (30–20–12 mg,
5-10-7.5 and 5 mg of prednisone). From W28, GCs
were tapered on a weekly basis by leaving out one
daily dose each week over a period of 6 weeks until
complete discontinuation.
A treat-to-target approach was used in a tight control set-
ting [15], aiming for a DAS28(CRP) ≤3.2. If patients failed
to reach this goal, treatment adjustments were made in
both groups from W8: first a MTX dose increase to 20 mg
weekly and then the addition of 10 mg of leflunomide daily.
Not reaching the target after these treatment adjustments
was considered an efficacy failure. Intramuscular and
intraarticular GC injections were allowed maximally every
8 weeks, except within 4 weeks preceding W16.
Outcome
The primary outcome was the proportion of patients in re-
mission at W16, defined as a DAS28(CRP) <2.6. Secondary
outcomes were the proportion of good responders accord-
ing to European League Against Rheumatism (EULAR)
Figure 1 Classification of patients into high- or low-risk group according to classic prognostic factors. ACPA, Anti–citrullinated protein antibodies;
DAS28(CRP), Disease Activity Score in 28 joints based on C-reactive protein; RF, Rheumatoid factor.
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Assessment Questionnaire (HAQ) response, patients hav-
ing a HAQ score of 0 at W16 and cumulative disease
activity.
Safety and toxicity
Patients were asked about experienced adverse events
(AEs) at each visit. Each reported AE was subtyped (tox-
icity, discomfort, infection, surgery or other) and evaluated
for relationship to the therapy, seriousness and severity by
the treating rheumatologist. In cases of toxicity, medica-
tion was adjusted according to a predefined scheme. Per-
sistent toxicity was considered a safety failure.
Statistical analysis
No power calculation was done, in view of the low-risk
subanalysis of the CareRA trial.
We performed an intention-to-treat (ITT) analysis by
χ2 test, Mann–Whitney U test, area under the curve
(AUC) and generalized estimating equation (GEE) ana-
lysis. Screening data were used to impute missing base-
line data and vice versa. A maximum likelihood model
was applied to impute missing data at W4, W8 and
W16. Missing data at the optional visit W12 were im-
puted by taking the mean of W8 and W16. SPSS version
20.0 software (IBM, Armonk, NY, USA) was used. A
P-value <0.05 was considered statistically significant.
Results
A group of 90 of the 380 patients in the CareRA trial
were stratified as low-risk patients, comprising 47 MTX-
TSU and 43 COBRA Slim patients. Both of these sub-
groups had similar baseline characteristics, which reflect
a mild eRA, with a moderate mean disease activity and
low numbers for erosions, RF and ACPA positivity(Table 1). One MTX-TSU and three COBRA Slim pa-
tients withdrew their consent before W16.
Efficacy
Primary and secondary outcomes
Remission was accomplished in 46.8% of MTX-TSU
patients and 65.1% of COBRA Slim patients (P = 0.081).
A good EULAR-defined response was achieved in 44.7% of
MTX-TSU and 58.1% of COBRA Slim patients (P = 0.202).
A clinically meaningful HAQ response was reached in
53.2% of MTX-TSU patients and 62.8% of COBRA Slim
patients (P = 0.357). Fewer patients had a HAQ score of 0
in the MTX-TSU group (23.4%) than in the COBRA Slim
group (51.2%) (P = 0.006). Table 2 describes these out-
comes in more detail.
Longitudinal analyses
The mean ± SD AUC DAS28(CRP) was 13.84 ± 4.58 and
11.18 ± 4.25 for the MTX-TSU and COBRA Slim patients,
respectively (P = 0.006) (Figure 2). GEE analysis showed a
better treatment effect on longitudinal disease activity of
COBRA Slim compared with MTX-TSU (P = 0.005).
Treatment adaptations
At W8, treatment adjustments were performed in 34.0% of
MTX-TSU patients and 23.3% of COBRA Slim patients
(P = 0.259). At W16, treatment adjustments were per-
formed in 21.3% of MTX-TSU patients and 16.3% of
COBRA Slim patients (P = 0.545). One COBRA Slim pa-
tient was considered to have experienced an efficacy failure
at W16.
Intraarticular GC injections were given in 21.3% of
MTX-TSU patients and 7.0% of COBRA Slim patients
(P = 0.054). Only one MTX-TSU patient received two
GC injections.
Table 1 Patients’ characteristics at baseline per treatment
groupa
MTX-TSU COBRA Slim
n = 47 n = 43
Age (yr) 51.02 ± 14.00 51.42 ± 14.42
BMI (kg/m2) 26.98 ± 4.22 25.40 ± 4.27
Female sex 80.9% 76.7%
Smoking status (ever) 38.3% 48.2%
Alcohol intake (yes) 61.7% 55.8%
Symptom duration (wk) 33.11 ± 62.21 34.42 ± 68.16
Disease duration (wk) 3.17 ± 6.62 1.86 ± 2.70
Employed before onset (yes) 66.0% 55.8%
Currently employed (yes) 57.4% 51.2%
Comorbidities present (yes) 66.0% 60.5%
Nocturnal pain (yes) 72.3% 48.8%
Morning stiffness (yes) 68.1% 53.5%
RF (yes) 23.4% 25.6%
Anti-CCP (yes) 23.4% 27.9%
Erosions (yes) 0.0% 2.3%
Total TJC 14.06 ± 8.61 13.14 ± 10.70
Total SJC 10.00 ± 6.98 10.93 ± 7.55
TJC28 9.49 ± 7.46 8.51 ± 7.80
SJC28 6.89 ± 6.11 7.79 ± 6.03
PGA (range: 0 to 100) 49.89 ± 22.99 48.60 ± 30.68
Pain (range: 0 to 100) 52.09 ± 23.23 48.23 ± 31.19
Fatigue (range: 0 to 100) 45.91 ± 22.07 39.40 ± 27.66
PhGA (range: 0 to 100) 48.34 ± 23.37 48.63 ± 20.80
ESR (mm/hr) 23.04 ± 16.90 30.00 ± 29.40
CRP (mg/L) 13.53 ± 18.62 20.14 ± 39.25
DAS28(ESR) 4.83 ± 1.68 4.88 ± 1.64
DAS28(CRP) 4.55 ± 1.63 4.50 ± 1.63
HAQ (range: 0 to 3) 0.99 ± 0.67 0.92 ± 0.85
aAlcohol intake, Consumption of any form of alcohol; Anti-CCP, Anti–citrullinated
protein antibodies; BMI, Body mass index; COBRA Slim, COmbinatie therapie bij
Reumatoïde Artritis; CRP, C-reactive protein; DAS28, Disease Activity Score in 28
joints; Disease duration, Time elapsed between diagnosis of RA and start of
treatment; ESR, Erythrocyte sedimentation rate; HAQ, Health Assessment
Questionnaire; Morning stiffness, Being stiff in the morning for at least 45 minutes;
MTX-TSU, Methotrexate with tight step-up, 15 mg of MTX weekly, no oral steroids
allowed; PGA, Patient global assessment; PhGA, Physician global assessment; RF,
Rheumatoid factor; SJC, Swollen joint count; Symptom duration, Time elapsed
between onset of symptoms and start of treatment; TJC, Tender joint count.
Values reported are proportions or mean ± standard deviation.
Table 2 Clinical outcomes at week 16 per treatment
groupa
MTX-TSU COBRA Slim P-value
n = 47 n = 43
DAS28(CRP) change 1.76 ± 1.68 2.12 ± 1.41 0.192
Remission 46.8% 65.1% 0.081
Low disease activity 72.3% 79.1% 0.458
Good EULAR response 44.7% 58.1% 0.202
Moderate EULAR response 72.3% 86.0% 0.111
HAQ change 0.40 ± 0.62 0.58 ± 0.64 0.267
Clinically meaningful HAQ change 53.2% 62.8% 0.357
HAQ score = 0 23.4% 51.2% 0.006
aCOBRA Slim, COmbinatie therapie bij Reumatoïde Artritis; DAS28(CRP),
Disease Activity Score in 28 joints based on C-reactive protein; DAS28(CRP)
change, Disease Activity Score in 28 joints at baseline minus Disease Activity
Score in 28 joints at week 16; EULAR, European League Against Rheumatism;
HAQ, Health Assessment Questionnaire; HAQ change, Baseline Health Assessment
Questionnaire score minus week 16 Health Assessment Questionnaire score;
MTX-TSU, Methotrexate with tight step-up, 15 mg of MTX weekly, no oral steroids
allowed. Clinically meaningful HAQ change is defined as a Health Assessment
Questionnaire score change >0.22. Remission is defined as DAS28(CRP) <2.6. Low
disease activity is defined as DAS28(CRP) ≤3.2. Good EULAR response is defined
as low disease activity with a DAS28(CRP) change >1.2. Moderate EULAR response
is defined as DAS28(CRP) change >1.2 or DAS28(CRP) change ≤5.1 and a
DAS28(CRP) change between 0.6 and 1.2. Values reported are proportions or
mean ± standard deviation. χ2 tests and Mann–Whitney U tests were applied
when appropriate. The significance level was set at 0.05.
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Until W16, therapy-related AEs were reported in 44.7%
of MTX-TSU patients and in 39.5% of COBRA Slim pa-
tients (P = 0.622). MTX-TSU was related to 32 AEs and
COBRA Slim to 30 AEs, with a similar distribution for
discomfort and toxicity (Table 3). In the MTX-TSU
group, 11 of 23 AEs related to discomfort were intestinalproblems (nausea and diarrhea), and 10 of 23 discomfort
problems in the COBRA Slim group were intestinal is-
sues (nausea and constipation). In the COBRA Slim
group, there were two cases of increased appetite. Fur-
thermore, 8 of 23 discomfort problems in the MTX-TSU
group and 8 of 23 AEs related to discomfort in the
COBRA Slim group were general malaise problems (diz-
ziness, agitation, headache and fatigue). There were
seven toxicity problems related to therapy in the MTX-
TSU group, comprising four cases of abnormal liver
values, one of abnormal kidney values, one of oral ulcer
and one of pyrosis. In the COBRA Slim group, there
were four toxicity problems related to therapy, compris-
ing two cases of alopecia, one of tendinitis and one of
stomatitis. The only infection in our study was an upper
respiratory tract infection in a MTX-TSU patient. No
serious AEs were registered. Additional file 2 gives a de-
tailed overview of the comorbidities.
Weight gain (mean ± SD) was 0.00 ± 2.44 kg in the
MTX-TSU group and 0.70 ± 3.16 kg in the COBRA Slim
group (P = 0.287). Body mass index gain (mean ± SD) was
0.01 ± 0.90 kg/m2 in the MTX-TSU group and 0.23 ±
1.12 kg/m2 in the COBRA Slim group (P = 0.286).
Discussion
We have demonstrated that, although the primary out-
come was not met at W16, low-risk patients with eRA
treated with MTX and a step-down GC bridging scheme
showed a better cumulative control of disease activity
Figure 2 Areas under the curve of Disease Activity Score in 28 joints based on C-reactive protein in each treatment group. COBRA Slim, COmbinatie
therapie bij Reumatoïde Artritis; DAS28(CRP), Disease Activity Score in 28 joints based on C-reactive protein; MTX-TSU, 15 mg of MTX weekly with tight
step-up; W, Week.
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with step-up MTX only, with a similar safety profile
maintained during the first 16 treatment weeks.
In both groups, favorable remission and low disease
activity scores were achieved after 16 weeks. Efficacy
scores did not differ at W16, which is probably due to
the limited number of patients included in this substudy,
as well as to a trend for more treatment modifications
and GC injections in the MTX-TSU group. The lower
cumulative disease activity in the COBRA Slim group
during the first 16 weeks of treatment might have import-
ant consequences for the future disease course [16,17].Table 3 Number of adverse events per treatment groupa
MTX-TSU COBRA Slim
n = 47 n = 43
AEs related to therapy 32 30










Serious AEs 0 0
aAE, Adverse event; COBRA Slim, COmbinatie therapie bij Reumatoïde Artritis;
MTX-TSU, Methotrexate with tight step-up, 15 mg of MTX weekly, no oral
steroids allowed. Protocol determines the severity rating of the adverse event:
mild (does not interfere with daily living), moderate (somewhat interferes with
daily living or medications needed to relieve event) or severe (incapacitating).Moreover, the speed of disease control and frequency in
treatment adaptations could also have differential effects
on the evolution of patient-centered outcomes.
In this study, we applied a step-down bridge GC
scheme that has two advantages over more traditional,
short-term, low-dose GC use [18]. First, high-dose or
moderately dosed GCs demonstrate, apart from slow
genomic effects, faster nongenomic effects, with a
more profound impact on the disease process [19,20].
Second, systematic and prolonged use of GCs is more
efficacious than on-demand use in the therapeutic time
window before maximum DMARD efficacy [6,21].
Intensive remission induction regimens in so-called
low-risk patients with eRA appear to be equally
advantageous as in high-risk patients with eRA, but
the appropriateness and performance of the currently
used prognostic parameters need further evaluation in
the long term [8].
A significant finding is the safety profile of both
groups. Patients in the MTX-TSU and COBRA Slim
groups showed comparable numbers and types of AEs
related to therapy in the period during which their treat-
ment schedules differed the most. Not much is known
about the safety of short-term GC use. Our study adds
to the much-needed evidence about GC use in the man-
agement of eRA [22,23] and shows that GC s are rela-
tively safe to use in a remission induction scheme in
patients with eRA, as well as in so-called mild RA. This
result is in contrast to some rheumatologists’ negative
perception of GC use in intensive treatment strategies in
eRA [24], whereas patients themselves are rapidly con-
vinced after GC administration [25].
This exploratory study has some limitations. First, the
total population in the low-risk arm was relatively small.
Power calculation for the CareRA study was done in
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tients were stratified as low-risk patients, we could not
reach the same power as in the high-risk arm. There-
fore, the results of our explorative study in the low-risk
arm should be interpreted with caution. Furthermore,
the low number of low-risk patients may be responsible
for the lack of statistical difference in the primary out-
come at W16. Second, we did not measure medication
adherence, and there was no blinding procedure, but
this is unavoidable in a pragmatic trial reflecting daily
clinical practice.
Third, we report the results after 16 weeks of treat-
ment, which is a relatively short time span in which
to evaluate the full impact of a treatment strategy.
This timing was chosen because there is increasing
evidence that long-term RA outcomes are mostly in-
fluenced by the initial success of treatment. Of course,
the ultimate effect of treat-to-target adaptations ac-
cording to the protocol cannot be evaluated within
this time window.
Our exploratory data are of importance in the ongoing
debate about the optimal initial treatment strategy for
eRA in daily practice [26]. Patients with RA who are nega-
tive for biomarkers such as RF and especially ACPA are
traditionally seen as having a better prognosis. Barra et al.
showed very clearly that this assumption is not always true
[27]. The absence of serum markers for RA cannot be
claimed to predict in general a milder disease course. This
means that patients conventionally perceived as having a
lower risk of a severe disease course should be treated ac-
cording to the same standards as high-risk patients. In this
study, we show that, just like high-risk patients, so-called
low-risk patients can be more successfully treated with an
intensive treatment strategy while having a similar safety
outcome as patients treated more conservatively. Until
such time that prognostic factors can reliably stratify pa-
tients by prognosis to specific treatment approaches, our
data suggest every patient with RA could benefit from an
upfront intensive treatment approach.
Conclusions
Patients with eRA perceived to be at low risk of a severe
disease course seem to improve more, at least in terms of
cumulative disease activity and functionality, if treated
intensively with MTX and a step-down bridge moderate-
dose GC scheme compared with MTX alone over the
course of 16 weeks.Additional files
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